David Malcom Rodman - 11 Dec 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Chief Medical Officer
Signature: /s/ Adam Levy, Attorney-in-fact
Issuer symbol: MLYS
Transactions as of: 11 Dec 2023
Net transactions value: +$2,710
Form type: 4
Filing time: 12 Dec 2023, 17:08:45 UTC
Previous filing: 14 Nov 2023
Next filing: 12 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Options Exercise	$2,710	+5,018	+33%	$0.5400^*	20,069	11 Dec 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLYS	Stock Option	Options Exercise	$0	-5,018	-7.1%	$0.000000	65,224	11 Dec 2023	Common Stock	5,018	$0.5400	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F2	The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.